ICON Public (NASDAQ:ICLR) Price Target Lowered to $225.00 at Robert W. Baird

ICON Public (NASDAQ:ICLR) had its price target trimmed by Robert W. Baird from $249.00 to $225.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

Several other equities analysts have also weighed in on the company. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. The Goldman Sachs Group dropped their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Redburn Atlantic started coverage on shares of ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price objective on the stock. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, TD Cowen lowered their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $292.45.

ICON Public Stock Up 0.7 %

Shares of NASDAQ:ICLR opened at $214.25 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The stock has a market cap of $17.67 billion, a price-to-earnings ratio of 23.89, a P/E/G ratio of 1.57 and a beta of 1.25. The company has a 50 day moving average of $257.93 and a 200-day moving average of $297.63. ICON Public has a one year low of $183.38 and a one year high of $347.72.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. ICON Public’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $3.10 EPS. On average, sell-side analysts forecast that ICON Public will post 13.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ICLR. Ashton Thomas Private Wealth LLC acquired a new stake in ICON Public during the second quarter worth about $54,000. ORG Partners LLC acquired a new position in ICON Public in the 2nd quarter valued at approximately $59,000. GAMMA Investing LLC raised its stake in shares of ICON Public by 50.0% during the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after purchasing an additional 42 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock worth $130,000 after purchasing an additional 226 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.